Dietary tributyrin supplementation in Parkinson's disease: An open-label target engagement study
View abstract on PubMed
Summary
This summary is machine-generated.Tributyrin, a prodrug of butyrate, shows promise for Parkinson's disease by improving brain butyrate levels and offering anti-inflammatory effects. This study found tributyrin safe and well-tolerated, with potential benefits for motor and cognitive symptoms.
Area Of Science
- Neuroscience
- Gastroenterology
- Pharmacology
Background
- Short-chain fatty acids like butyrate are crucial for gut-brain axis signaling and have therapeutic potential for neurodegenerative diseases.
- Oral butyrate supplementation faces challenges due to rapid metabolism, leading to low systemic and brain concentrations.
- Tributyrin, a butyrate prodrug, offers improved pharmacokinetics compared to sodium butyrate.
Purpose Of The Study
- To assess the safety, tolerability, and target engagement of tributyrin supplementation in individuals with Parkinson's disease.
- To investigate tributyrin's effects on brain butyrate uptake and systemic inflammation.
- To explore potential clinical benefits of tributyrin on cognitive and motor functions in Parkinson's disease.
Main Methods
- An open-label, 30-day study involving 14 Parkinson's disease patients and 3 controls receiving oral tributyrin (500 mg TID).
- Positron Emission Tomography (PET) imaging with [11C]butyrate to measure organ-specific butyrate uptake before and after supplementation.
- Clinical assessments of cognitive, motor, and neurobehavioral functions were performed pre- and post-intervention.
Main Results
- Tributyrin supplementation demonstrated a favorable safety profile with high adherence rates.
- PET imaging confirmed target engagement, showing increased butyrate uptake in various organs.
- Improvements were observed in exploratory cognitive and motor assessments, alongside systemic anti-inflammatory effects.
Conclusions
- Tributyrin is safe and well-tolerated in Parkinson's disease patients, with evidence of target engagement and potential clinical benefits.
- Tributyrin may modulate brain butyrate availability and exert systemic anti-inflammatory effects.
- Further large-scale, placebo-controlled trials are warranted to confirm tributyrin's efficacy as a complementary therapy for Parkinson's disease.
Related Concept Videos
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Detailed History: Understanding the patient's symptoms is critical. It includes inquiring about abdominal pain, weight loss, and digestive issues, which are common in chronic pancreatitis.
Physical Examination: This might reveal abdominal tenderness, jaundice, and signs of malnutrition,...

